INDP
Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.22
+5.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.3%
- EBIT
- +9.6%
- EPS
- +32.2%
- Free cash flow
- -1.4%
- Operating cash flow
- -1.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +57.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -38.8%
- EBIT
- -29.1%
- Net income
- -38.8%
- EPS
- +52.0%
- Free cash flow
- -20.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026